Quintiles And Eisai Collaborate To Develop Cancer Compounds
This article was originally published in PharmAsia News
Moving beyond the traditional contract research organization model, Quintiles will collaborate with Eisai to perform 11 proof-of-concept trials on six oncology compounds in a deal announced Oct. 30
You may also be interested in...
Eisai’s lenvatinib achieved proof of concept for melanoma, and now Eisai steps back into the picture for Phase III.
Pfizer Inc. and Eisai Co.'s downsized R&D budgets seek no-risk solutions with SFJ Pharma.
TOKYO - Takeda Pharmaceuticals has teamed with contract research organizations Covance and Quintiles to move toward a "fully virtual outsourcing model," the company announced Feb. 15